M. Slaoui

发表

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

J. Sadoff, I. Schneider, W. Ballou, 1995, The Journal of infectious diseases.

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

Joe D. Cohen, W. Ballou, K. Kester, 1997, The New England journal of medicine.

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

G. Wortmann, Joe D. Cohen, R. Wirtz, 1998, The Journal of infectious diseases.

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

A. Hill, W. Ballou, M. Plebanski, 1999, The Journal of infectious diseases.

Enumeration of lymphokine‐secreting cells as a quantitative measure for cellular immune responses in rhesus macaques

J. Heeney, M. Slaoui, P. Melde, 1995, Journal of medical primatology.

Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b - PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine

M. Knuf, H. Schmitt, A. Schuind, 1996, European Journal of Pediatrics.

Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells

B. Rouse, E. Manickan, M. Dewerchin, 1995, Journal of virology.

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system.

P. van Damme, G. Leroux-Roels, A. Meheus, 1998, Vaccine.

Hepatitis B virus-specific cytotoxic T lymphocyte responses in patients with acute and chronic hepatitis B virus infection.

G. Leroux-Roels, E. van Hecke, P. Pala, 1994, Journal of hepatology.

Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine

M. Knuf, R. Clemens, M. Slaoui, 1996, Infection and immunity.

, P acellular pertussis vaccine . infants after vaccination with a tricomponent Pertussis-specific cell-mediated immunity in

M. Knuf, H. Schmitt, R. Clemens, 1996 .

Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.

D. Bernstein, L. Stanberry, N. Bourne, 2003, The Journal of infectious diseases.

Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination.

M. Knuf, H. Schmitt, M. Slaoui, 1999, Vaccine.

Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach.

M. Slaoui, Matthew Hepburn, 2020, The New England journal of medicine.

Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine.

B. Graham, K. Neuzil, J. Johnson, 1997, Vaccine.

Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice.

T. L. Keadle, J. Pepose, M. Slaoui, 1997, The Journal of infectious diseases.

A Method to Detect Hepatitis B Virus-specific Cytotoxic T Lymphocytes in Patients with Acute and Chronic HBV Infection

G. Leroux-Roels, E. Hecke, P. Pala, 1994 .

Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features and perspectives

S. Garner, Carlo Incerti, Y. le Cam, 2014, Orphanet Journal of Rare Diseases.

Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs.

D. Bernstein, N. Bourne, M. Schleiss, 1995, The Journal of infectious diseases.

A hepatitis B vaccine formulated with a novel adjuvant system.

G. Leroux-Roels, M. Kundi, I. Desombere, 2000, Vaccine.

The potential epidemiological impact of a genital herpes vaccine for women

G. Garnett, G. Dubin, M. Slaoui, 2004, Sexually Transmitted Infections.

Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

F. Aoki, D. Bernstein, L. Stanberry, 2002, The New England journal of medicine.

Methods and compositions for inducing protective immunity against disease and / or infection filoviruses

M. Slaoui, R. Ballou, Hoof Johann Jules Urbain Van, 2016 .

Drug discovery: A jump-start for electroceuticals

Brian Litt, Kevin J. Tracey, Edward S. Boyden, 2013, Nature.

Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents.

D. Bernstein, F. Biro, L. Stanberry, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy of the herpes simplex virus types 1 and 2 mutant viruses to confer protection against zosteriform spread in mice.

B. Rouse, S. Brown, M. Slaoui, 1993, Viral immunology.

Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus).

G. Prince, D. Porter, J. Prieels, 1999, Laboratory investigation; a journal of technical methods and pathology.

Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease.

G. Prince, N. Garçon, D. Porter, 2001, Vaccine.

The rise and fall of rosiglitazone: reply.

M. Slaoui, 2010, European heart journal.

Cell-mediated immunity after pertussis vaccination and after natural infection.

M. Knuf, H. Schmitt, R. Clemens, 1997, Developments in biological standardization.

The potential epidemiological impact of a genital herpes vaccine for women

G. Dubin, M. Slaoui, T. Darcis, 2004, Sexually Transmitted Infections.